DEF: INmune Bio Schedules 2026 Annual Meeting, Proposes Stock Plan Update

INmune Bio Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 16, 2026, to elect directors, ratify auditors, and approve an updated stock incentive plan.

Summary

• INmune Bio Inc. is holding its Annual Meeting of Stockholders virtually on June 16, 2026, at 10:00 AM Eastern Time.
• Key proposals include the election of five directors, ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for the year ending December 31, 2026, and approval of the Third Amended and Restated INmune Bio Inc. 2021 Stock Incentive Plan.
• The company is seeking to increase the number of shares authorized under the stock incentive plan by 2,658,525 shares, bringing the total to 9,158,525 shares.
• An 'evergreen' provision is proposed to automatically increase the share reserve annually from 2027 through 2031.
• The record date for determining stockholders entitled to vote is April 20, 2026, with 26,585,258 shares of common stock outstanding.
• The Board of Directors recommends a FOR vote on all three proposals.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, as it addresses standard corporate governance matters and aims to provide long-term incentives, but also carries potential for shareholder dilution.

Positives

• The company is proactively seeking stockholder approval for its stock incentive plan, aiming to ensure continued ability to incentivize employees and retain talent.
• The proposed increase in authorized shares under the incentive plan (2,658,525 shares) and the evergreen provision are designed to provide long-term flexibility for compensation and retention.
• The company has a clear process for director elections and auditor ratification, indicating good corporate governance.
• The virtual meeting format allows for broader participation from stockholders globally.

Negatives

• The proposed increase in authorized shares under the stock incentive plan could lead to dilution of earnings per share, book value per share, and stock ownership for existing shareholders.
• The company's financial performance, as indicated by the Pay Versus Performance table, shows a net loss for 2025 and 2024, which may be a concern for investors.
• The dismissal of Marcum LLP as the independent registered public accounting firm and the engagement of CBIZ CPAs P.C. might raise questions, although no disagreements were reported.

Risks

• The issuance of new shares under the Third Amended and Restated 2021 Stock Incentive Plan may dilute the ownership and voting rights of existing stockholders.
• The 'evergreen' provision in the stock incentive plan could lead to significant future dilution if not carefully managed.
• The company has experienced net losses in recent fiscal years, which could impact future financial stability and stock performance.
• The potential for broker non-votes on non-routine matters (director elections and stock incentive plan approval) could affect the outcome of these proposals if stockholders do not provide voting instructions.

Future Outlook

The company is seeking approval for its Third Amended and Restated 2021 Stock Incentive Plan, which includes an 'evergreen' provision to automatically increase the number of shares reserved for grants annually from 2027 through 2031. This aims to provide ongoing flexibility for employee incentives and retention.

Management Comments

• The Board of Directors recommends that stockholders vote FOR the election of each of the nominees for director.
• The Board of Directors recommends that stockholders vote FOR the ratification of the appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the year ending December 31, 2026.
• The Board of Directors recommends that stockholders vote FOR the approval of the Third Amended and Restated 2021 Plan.
• David Moss, Chief Executive Officer and Secretary, signed the notice of the annual meeting.

Industry Context

StockSavvy.ai notes that INmune Bio's proposal to amend its stock incentive plan, including an evergreen provision, is a common strategy in the biotechnology sector to attract and retain talent in a competitive market. However, the potential for dilution requires careful monitoring by investors.

Comparison to Industry Standards

• The proposed increase of 2,658,525 shares, bringing the total to 9,158,525, represents approximately 10% of the current outstanding shares (26,585,258 as of April 20, 2026). This is a significant, but not unusual, increase for a growing biotech company seeking to maintain its equity compensation pool.
• The 'evergreen' provision, allowing for annual increases of up to 10% of outstanding shares, is a standard feature in many technology and biotech stock incentive plans, designed to ensure a consistent supply of shares for future grants.
• The ratification of an independent auditor is a routine governance practice across all publicly traded companies.

Management Changes

Corporate Governance

Related Party Transactions

• Payments totaling $132,000 in 2025 and $321,000 in 2024 were made to UCL for medical research, where UCL is a subsidiary of the University of London, and the Company's Chief Scientific and Manufacturing Officer is a professor at the University of London.
• Payments totaling $41,000 in 2025 and $324,000 in 2024 were made to AmplifyBio for medical research. AmplifyBio ceased operations in 2025, and its former CEO is on the Company's board of directors.

Stakeholder Impact

• Shareholders: Potential dilution from the proposed stock incentive plan increase, but also potential for increased employee retention and performance driving value.
• Employees: Increased opportunity for equity-based compensation and incentives through the stock incentive plan.
• Management: Continued oversight and compensation adjustments through the compensation committee.
• Auditors: Ratification of CBIZ CPAs P.C. as the independent auditor for 2026.

Next Steps

• Stockholders will vote on the proposed items at the Annual Meeting on June 16, 2026.
• The company will file final voting results in a Form 8-K with the SEC following the meeting.
• If approved, the Third Amended and Restated 2021 Stock Incentive Plan will be implemented, with the 'evergreen' provision commencing in 2027.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting. While it proposes standard corporate actions like director elections and an updated stock incentive plan, it does not contain significant new financial performance data or strategic shifts that would warrant a strong buy or sell recommendation. The potential for dilution from the stock plan is a consideration, but the overall nature of the proposals suggests a 'hold' stance pending further operational or financial updates.

Keywords

INmune Bio, Proxy Statement, Annual Meeting, Stock Incentive Plan, Director Election, Auditor Ratification, Equity Awards, Shareholder Vote, Corporate Governance, Dilution